Effective management of type 2 diabetes: The role of individualised patient care | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

(linagliptin) 5 mg tablets

This promotional webcast has been developed, organised and funded by Boehringer Ingelheim.
Boehringer Ingelheim products will be discussed during this event.

Tuesday 13 July at 12.30 and 19.00

National and international guidelines for management of adult type 2 diabetes recognise the importance of individualised patient care that is respectful of and responsive to individual patient preferences and barriers such as comorbidities.1,2 Although not without challenges, taking a patient-centred approach has been shown to have a positive impact on patient outcomes.3

Join us for a live webcast on Tuesday 13 July at 12.30 and 19.00 hosted by Dr Sarah Jarvis, General Practitioner, London and Clinical Director at Patient.info and Paul Dromgoole, Clinical Lecturer in Diabetes and Diabetes Specialist Nurse (part-time), Lincolnshire. This webcast will discuss the challenges of optimising and individualising treatment and explore the potential role of the dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta (linagliptin) in the management of type 2 diabetes in adults. Tools which can be used during consultations to help empower patients will be introduced and finally, a hypothetical case study will be used to apply the considerations discussed to everyday clinical practice.

References

  1. Davies MJ et al. Diabetes Care 2018;41:2669–2701.
  2. NICE (2015) Type 2 diabetes in adults: Management. Available at: www.nice.org.uk/guidance/ng28 (accessed April 2021)
  3. Powell PW et al. Curr Diabetes Rev 2015;11:222–230

Programme

5 mins

Welcome and introduction

Sarah Jarvis

15 mins

Effective management of adults with type 2 diabetes: goals and challenges

Sarah Jarvis

Paul Dromgoole

15 mins

Shared decision making in type 2 diabetes: the role of effective consultation skills for patient empowerment

Paul Dromgoole

10 mins

Live Q&A

Sarah Jarvis

Paul Dromgoole

Speakers

Dr Sarah Jarvis MBE, FRCGP

GP, Medical Broadcaster and Clinical Director, Patient.info

Dr Sarah Jarvis trained at Cambridge and Oxford universities and has been a partner in the same inner city general practice for 26 years. She is an active medical writer and broadcaster and is the BBC Radio 2 doctor and the doctor to The One Show on BBC 1. Besides these roles, she has been a regular contributor to a variety of medical journals including Update, Doctor, Practice Nurse and the British Journal of Cardiology. Dr Jarvis is past chair of the Healthcare Committee of HEART UK, the cholesterol charity and is a member of the advisory board for the British Journal of Cardiology. Dr Jarvis has a particular interest in cardiovascular disease, diabetes and women’s health.

In 2021, Dr Jarvis was appointed Visiting Professor of General Practice at the University of Huddersfield.

Paul Dromgoole

Clinical Lecturer in Diabetes and Diabetes Specialist Nurse (part-time), Lincolnshire

Paul Dromgoole has over 18 years experience in diabetes management in primary care and secondary care settings in Brighton, Leicester and York. More recently, he has worked as a half-time Lecturer Practitioner in Diabetes at the University of York, teaching on diabetes programmes from Pre-registration up to Master’s levels. He is formerly an external examiner at the University of Ulster. Paul has extensive experience of supporting General Practice in clinical decision-making and best practice in diabetes management.

Paul now combines a two-day a week role as Clinical Nurse Specialist – Diabetes, with freelance lecturing work with a variety of organisations, including GP training companies. His interests with diabetes are particularly around managing clinical risk, patient empowerment and guiding effective health behaviour change.

What does this programme offer?

Live Q&A session with Dr Sarah Jarvis and Paul Dromgoole ready to answer your questions

On-demand resources – access education at times that work for you

Register for free today and gain access to this event

UK only

Boehringer Ingelheim UK Request a call from a representative

Sign up

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI’s products, services and events.

Effective management of type 2 diabetes in adults:

The role of individualised patient care

Tuesday 13 July at 12.30 and 19.00

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:

This promotional webcast has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring
company and the speakers prior to the publication. The speakers have received an honorarium to take part in this promotional webcast. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on
0800 328 1627 (freephone) (UK) or 01 2913960, Fax: +44 1344 742661, or by e-mail: PV_local_UK_Ireland@boehringer-ingelheim.com (IRE).

PC-GB-104112 | April 2021

(linagliptin) 5 mg tablets

©2018-2021 Boehringer Ingelheim GmbH All rights reserved.

(linagliptin) 5 mg tablets

©2018-2021 Boehringer Ingelheim GmbH All rights reserved.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.